Barclays
OTLK icon

Barclays’s Outlook Therapeutics OTLK Stock Holding History

Barclays’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35 Buy
+61
New +$58 ﹤0.01% 5098
2026
Q1 		– Sell
-1
Closed -$2 – 5323
2025
Q4 		$2 Hold
1
– – ﹤0.01% 5181
2025
Q3 		$1 Sell
1
-100
-99% -$173 ﹤0.01% 5450
2025
Q2 		$162 Sell
101
-16,939
-99% -$27K ﹤0.01% 5096
2025
Q1 		$20.8K Sell
17,040
-6,840
-29% -$12K ﹤0.01% 4786
2024
Q4 		$45.1K Buy
23,880
+2,937
+14% +$12.1K ﹤0.01% 4781
2024
Q3 		$112K Buy
20,943
+18,249
+677% +$134K ﹤0.01% 4539
2024
Q2 		$19.9K Sell
2,694
-2,802
-51% -$22.5K ﹤0.01% 4438
2024
Q1 		$65.6K Sell
5,496
-5,299
-49% -$42.8K ﹤0.01% 4558
2023
Q4 		$85.1K Buy
10,795
+9,447
+701% +$79.9K ﹤0.01% 4673
2023
Q3 		$5.96K Sell
1,348
-200
-13% -$4.42K ﹤0.01% 4367
2023
Q2 		$53.9K Sell
1,548
-2,412
-61% -$65.8K ﹤0.01% 3807
2023
Q1 		$86.3K Buy
3,960
+2,370
+149% +$53K ﹤0.01% 4258
2022
Q4 		$34.4K Buy
1,590
+1,339
+533% +$29.1K ﹤0.01% 4674
2022
Q3 		$6K Sell
251
-46
-15% -$1.07K ﹤0.01% 4467
2022
Q2 		$6K Sell
297
-628
-68% -$18.1K ﹤0.01% 4752
2022
Q1 		$32K Sell
925
-4,480
-83% -$140K ﹤0.01% 4288
2021
Q4 		$147K Buy
5,405
+3,585
+197% +$128K ﹤0.01% 3643
2021
Q3 		$79K Buy
1,820
+969
+114% +$46.8K ﹤0.01% 3991
2021
Q2 		$42K Buy
851
+382
+81% +$17.7K ﹤0.01% 4212
2021
Q1 		$21K Buy
+469
New +$18K ﹤0.01% 4361
2020
Q2 		– Sell
-1,761
Closed -$21K – 6077
2020
Q1 		$21K Hold
1,761
– – ﹤0.01% 5627
2019
Q4 		$21K Buy
+1,761
New +$41K ﹤0.01% 5975
2019
Q2 		– Sell
-1
Closed – – 7160
2019
Q1 		$0 Buy
+1
New +$141 ﹤0.01% 7239

Other funds holding OTLK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Gilpin Wealth Management
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Royal Fund Management
Royal Fund Management Lady Lake, Florida $1.26B AUM 23.83% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Christensen King & Associates Investment Services
Christensen King & Associates Investment Services Richland, Washington $276M AUM 13.14% 1-Year Est. Return
Flower City Capital
Flower City Capital Pittsford, New York $234M AUM 15.69% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Barclays's OTLK Position: Q3 2026 in Review

Barclays opened a new position in Outlook Therapeutics (OTLK) in Q3 2026: 61 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #5098 among its holdings. This is a return to the name: Barclays previously reported a position in OTLK as recently as Q4 2025.

Barclays first reported a position in OTLK in Q1 2019 and has held it in 24 quarters since. The position peaked at $147K in Q4 2021. 28 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

  • Barclays held 61 shares of Outlook Therapeutics worth $35 as of Q3 2026.
  • Outlook Therapeutics was a new Barclays position in Q3 2026.
  • Outlook Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5098 holding.
  • Barclays first reported a position in Outlook Therapeutics in Q1 2019 and has held it in 24 quarters since.
  • Barclays's Outlook Therapeutics position peaked at $147K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.